[go: up one dir, main page]

IL118349A - 3-substituted oxindole derivatives and pharmaceutical compositions for opening of the large-conductance calcium-activated potassium channels comprising them - Google Patents

3-substituted oxindole derivatives and pharmaceutical compositions for opening of the large-conductance calcium-activated potassium channels comprising them

Info

Publication number
IL118349A
IL118349A IL11834996A IL11834996A IL118349A IL 118349 A IL118349 A IL 118349A IL 11834996 A IL11834996 A IL 11834996A IL 11834996 A IL11834996 A IL 11834996A IL 118349 A IL118349 A IL 118349A
Authority
IL
Israel
Prior art keywords
opening
pharmaceutical compositions
potassium channels
activated potassium
conductance calcium
Prior art date
Application number
IL11834996A
Other languages
English (en)
Other versions
IL118349A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL118349A0 publication Critical patent/IL118349A0/xx
Publication of IL118349A publication Critical patent/IL118349A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IL11834996A 1995-06-07 1996-05-21 3-substituted oxindole derivatives and pharmaceutical compositions for opening of the large-conductance calcium-activated potassium channels comprising them IL118349A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (2)

Publication Number Publication Date
IL118349A0 IL118349A0 (en) 1996-09-12
IL118349A true IL118349A (en) 2000-07-26

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11834996A IL118349A (en) 1995-06-07 1996-05-21 3-substituted oxindole derivatives and pharmaceutical compositions for opening of the large-conductance calcium-activated potassium channels comprising them

Country Status (25)

Country Link
US (2) US5565483A (xx)
EP (1) EP0747354B1 (xx)
JP (1) JP4011135B2 (xx)
KR (1) KR100432157B1 (xx)
CN (1) CN1076348C (xx)
AR (1) AR004493A1 (xx)
AT (1) ATE195515T1 (xx)
AU (1) AU707760B2 (xx)
BR (1) BR1100180A (xx)
CA (1) CA2176183C (xx)
CZ (1) CZ289248B6 (xx)
DE (1) DE69609772T2 (xx)
DK (1) DK0747354T3 (xx)
ES (1) ES2148685T3 (xx)
GR (1) GR3034523T3 (xx)
HU (1) HU222046B1 (xx)
IL (1) IL118349A (xx)
NO (1) NO304829B1 (xx)
NZ (1) NZ286748A (xx)
PL (1) PL184660B1 (xx)
PT (1) PT747354E (xx)
RU (1) RU2165925C2 (xx)
SG (1) SG70572A1 (xx)
TW (1) TW384284B (xx)
ZA (1) ZA964327B (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
HUP0002449A3 (en) * 1997-05-30 2001-12-28 Bristol Myers Squibb Company W Process for producing 3-fluoro oxindole derivatives and intermediates of the preparation
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
US5972961A (en) * 1997-08-28 1999-10-26 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
AU5487199A (en) * 1998-08-14 2000-03-06 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
AU1648600A (en) * 1998-12-04 2000-06-26 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
WO2000034244A1 (en) 1998-12-04 2000-06-15 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
EP1198456B1 (en) * 1999-08-03 2007-09-19 Abbott Laboratories Potassium channel openers
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP1265849B1 (en) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
CN1222288C (zh) * 2000-06-29 2005-10-12 神经研究公司 3－取代的羟吲哚衍生物作为kcnq钾通道调节剂的用途
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
CA2410972A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002030868A1 (en) * 2000-10-13 2002-04-18 Bristol-Myers Squibb Company Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
EP1363624A2 (en) * 2001-02-20 2003-11-26 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
IL157313A0 (en) 2001-02-20 2004-02-19 Bristol Myers Squibb Co Modulators of kcnq potassium channels and uses thereof
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
BR0210721A (pt) * 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
RS81904A (sr) * 2002-03-20 2007-02-05 Bristol-Myers Squibb Company, Fosfatni prolekovi fluorooksindola
WO2004002962A1 (en) * 2002-06-26 2004-01-08 Poseidon Pharmaceuticals A/S Novel benzimidazol-2-one derivatives and their use
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
WO2004035037A2 (en) * 2002-10-21 2004-04-29 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
EP1639091B1 (en) 2003-06-17 2012-12-05 California University Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome p450
CA2532248A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
WO2005035498A1 (ja) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TW200716106A (en) * 2005-04-24 2007-05-01 Wyeth Corp Methods for modulating bladder function
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
BRPI0613430A2 (pt) * 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8026085B2 (en) * 2006-08-04 2011-09-27 California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
WO2009045381A1 (en) * 2007-10-04 2009-04-09 Merck & Co., Inc. N-substituted oxindoline derivatives as calcium channel blockers
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (en) 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
SMT202100222T1 (it) 2015-04-29 2021-05-07 Janssen Pharmaceutica Nv Azabenzimidazoli e loro uso come modulatori del recettore ampa.
WO2016176463A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Indolone compounds and their use as ampa receptor modulators
KR20190119602A (ko) 2017-02-24 2019-10-22 오비드 테라퓨틱스 인크. 발작 장애들을 치료하는 방법들
CA3077659A1 (en) 2017-10-09 2019-04-18 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and trpv1 channels and uses thereof
JP7063401B2 (ja) * 2019-01-25 2022-05-09 Ｊｆｅスチール株式会社 高マンガン鋼鋳片の製造方法、および、高マンガン鋼鋼片または鋼板の製造方法
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
SK278514B6 (en) * 1990-09-25 1997-08-06 Andreas Kiener Rhodococcus erythropolis microorganism and a method for producing hydroxylated pyrazines and quinoxalines
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
ATE195515T1 (de) 2000-09-15
JP4011135B2 (ja) 2007-11-21
BR1100180A (pt) 2000-03-14
PT747354E (pt) 2000-11-30
KR100432157B1 (ko) 2004-10-06
US5602169A (en) 1997-02-11
AR004493A1 (es) 1998-12-16
GR3034523T3 (en) 2000-12-29
JPH08333336A (ja) 1996-12-17
DE69609772T2 (de) 2001-04-12
HU222046B1 (hu) 2003-04-28
ZA964327B (en) 1997-11-28
NO304829B1 (no) 1999-02-22
EP0747354B1 (en) 2000-08-16
EP0747354A1 (en) 1996-12-11
SG70572A1 (en) 2000-02-22
AU707760B2 (en) 1999-07-22
NO962232L (no) 1996-12-09
KR970001324A (ko) 1997-01-24
AU5475796A (en) 1996-12-19
HUP9601547A1 (en) 1997-09-29
CA2176183C (en) 2010-03-30
PL184660B1 (pl) 2002-11-29
HK1003301A1 (en) 1998-10-23
PL314672A1 (en) 1996-12-09
US5565483A (en) 1996-10-15
ES2148685T3 (es) 2000-10-16
NZ286748A (en) 1998-08-26
CA2176183A1 (en) 1996-12-08
CN1144800A (zh) 1997-03-12
RU2165925C2 (ru) 2001-04-27
CZ289248B6 (cs) 2001-12-12
DE69609772D1 (de) 2000-09-21
NO962232D0 (no) 1996-05-31
DK0747354T3 (da) 2000-09-18
CN1076348C (zh) 2001-12-19
IL118349A0 (en) 1996-09-12
HU9601547D0 (en) 1996-08-28
TW384284B (en) 2000-03-11
CZ161896A3 (en) 1997-03-12

Similar Documents

Publication Publication Date Title
IL118349A (en) 3-substituted oxindole derivatives and pharmaceutical compositions for opening of the large-conductance calcium-activated potassium channels comprising them
IL120699A0 (en) Indole derivatives and pharmaceutical compositions containing them
NZ299693A (en) 1,4-dioxino derivatives of indole and quinoline; pharmaceutical compositions
AU2647597A (en) Oxindole derivatives
ZA968945B (en) 1,3-Dihydro-indol-2-one derivatives process for their preparation and the pharmaceutical compositions containing them
IL125377A (en) Benzyl(idene)-lactam derivatives and pharmaceutical compositions containing them
HUP9601285A3 (en) Substituted n-(indole-2-carbonyl)-beta-alaninamides and derivatives and pharmaceutical compositions containing them
AU4265496A (en) Perhydroisoindole derivatives as antagonists of substance p
HUP0100723A3 (en) Indole derivatives, process for producing them and pharmaceutical compositions containing them
AU4400597A (en) Indole derivatives
AU5856898A (en) Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
IL117331A0 (en) Indole derivatives their preparation and pharmaceutical compositions containing them
HUP0100680A3 (en) Indole derivatives and medicinal compositions containing the same
AU7000796A (en) Heteroaryl-substituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
HUP0004294A3 (en) Indole derivatives, pharmaceutical compositions containing them and process for producing them
AU7449198A (en) Phthalimide derivatives and pharmaceutical containing said derivatives
AU7237998A (en) Indole derivatives and mono- and diazaindole derivatives
AU1671597A (en) Indole derivatives
AU3710695A (en) Quinolonylcarboxyerythromycin derivatives and pharmaceutical compositions containing them
AU3083795A (en) Indoline and azaindoline derivatives as 5-ht1d alpha receptor agonists
AU6370196A (en) Indole derivatives
IL116956A (en) Substituted indole derivatives their preparation and pharmaceutical compositions containing them
IL119844A (en) Substituted indole derivatives and pharmaceutical compositions containing them
AU4355296A (en) Indole derivatives
AU3107497A (en) Asialotrisaccharide moranoline derivatives and drugs

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees